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Abstract 
The use of interleukin-2 (IL-2) for the stimulation of an effector immune response 
against metastatic cancer dates back to the early 1980s. Administration of 
unmodified IL-2, either alone or together with antigen-specific approaches, has 
resulted in remarkably long-term survival of some patients suffering from metastatic 
melanoma. However, such treatment is usually hampered by the appearance of toxic 
adverse effects, which has motivated the engineering of modified IL-2 formulations 
showing reduced toxicity while being more potent at stimulating anti-tumor effector 
immune cells. In this review we summarize and discuss the features and biological 
relevance of several enhanced IL-2 formulations, compare these to IL-15-based 
therapeutics, and try to foreshadow their potential in immunological research and 
immunotherapy. 
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Introduction 
Interleukin-2 (IL-2) is a small 15.5 kDa four -helical bundle cytokine, which plays 
crucial roles both during the resting and activated states of the immune system [1]. 
The main function of IL-2 during steady-state conditions appears to lie in the 
development and survival of CD4+ forkhead box p3 (Foxp3)+ regulatory T-cells 
(Tregs), thus governing peripheral immune tolerance [2]. Conversely, during an 
immune response, IL-2 acts as a 'growth factor' of effector immune cells by 
supporting the proliferation and expansion of effector and memory T-cells and natural 
killer (NK) cells, and also enhances effector functions of these cells [1-3].  
 IL-2 can bind to three different IL-2 receptors (IL-2R): IL-2R (CD25) alone, a 
heterodimer of IL-2R (CD122) and IL-2R (also referred to as common -chain 
receptor, c), and a heterotrimer of CD25, CD122 and c, which are called the low-, 
intermediate-, and high-affinity IL-2R, respectively (Figure 1A). CD122 and c are 
crucial for signaling upon IL-2 binding, whereas CD25 does not appear to signal but 
increases receptor affinity [3,4]. 
While c expression remains rather stable, CD25 is up-regulated on recently 
activated T-cells, along with a moderate elevation of CD122, thereby leading to 
increased sensitivity of these cells to autocrine and paracrine IL-2. On resting 
immune cells, CD25 is mainly confined to Tregs, which also express the other IL-2R 
subunits, thus showing high sensitivity to IL-2. Recently antigen-stimulated T-cells 
express CD25 mirroring their high dependency on IL-2 during the expansion phase 
[3,5]. Interestingly, during later stages of an immune response, antigen-experienced 
(memory) CD8+ T-cells and NK cells express very high levels of CD122 (higher than 
on Tregs) along with c and are thus able to compete with Tregs for IL-2 [6,7]. 
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 IL-2 is a secreted primarily by activated CD4+ T-cells, but also CD8+ T-cells, 
NK and NKT-cells, DCs, and mast cells are able to produce IL-2 following activation 
[1,2,8]. 
 Owing to its potent T-cell growth-stimulating properties, IL-2 administration has 
been successfully used since the early 1980s as a cancer immunotherapy [9-11]. 
There, IL-2 proved beneficial in patients with end-stage metastatic melanoma or renal 
cell carcinoma (Figure 2), especially when given as high-dose (HD) IL-2 consisting of 
600'000-720'000 international units per kg body weight per infusion, administered 
every 8 hours for a maximum of 14 doses [9,11]. However, the widespread use of IL-
2 is hampered by dose-dependent adverse effects, such as hypotension, pulmonary 
edema, liver cell damage and renal failure. Pathophysiologically, these phenomena 
appear to result from increased vascular permeability leading to vascular leak 
syndrome (VLS) [12,13]. 
 Another complicating factor is that IL-2 has a short half-life of 20-30 minutes in 
the blood in vivo, as it is rapidly cleared by the renal system upon intravenous (iv) 
injection [12,14,15]. Moreover, HD IL-2 expands Tregs, which can suppress tumor-
specific effector CD8+ T-cell responses [16,17]. 
 Several strategies have been employed to optimize the efficacy of IL-2 for 
tumor immunotherapy. These include the use of particular anti-IL-2 monoclonal 
antibodies (mAb), which bind recombinant or endogenous IL-2 and form so-called IL-
2/anti-IL-2 mAb complexes (IL-2-cx), thereby preferentially directing IL-2 to immune 
cells expressing high levels of CD122. Other strategies encompass the introduction 
of specific mutations to IL-2 (IL-2 muteins) to favor binding to either CD25 or CD122, 
i.e. dimeric or trimeric IL-2Rs, thus preferentially stimulating certain immune cell 
subsets. Alternatively, IL-2 has been linked to mAbs specific for tumor bed or tumor 
vasculature thereby generating so-called IL-2 fusion proteins (IL-2-FP) (Table 1). 
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 In this review, we discuss recent developments in IL-2 tumor immunotherapy 
by focusing on IL-2-based compounds with improved in vivo properties, and compare 
these strategies to alternative therapeutics targeting IL-2R subunits, such as IL-15-
based approaches. 
 
IL-2/anti-IL-2 mAb complexes 
IL-2-cx are generated by the association of murine or human IL-2 with specific mAbs 
(such as clone S4B6 for murine IL-2), whereby the mAb directs IL-2 to cells 
expressing high levels of CD122 (in addition to c), including memory CD8+ T-cells 
and NK cells (Figure 1B) [6]. Use of murine or human IL-2-cx in one or more 
treatment cycles consisting of 3-7 daily injections induced robust expansion of CD8+ 
T-cells by 20-100 fold and of NK cells by 20-30 fold in vivo [6,18], which translated 
into significant anti-tumor immune responses and inhibition of tumor growth in several 
mouse models [15,18,19]. IL-2-cx immunotherapy show several advantages over HD 
IL-2, such as prolonged in vivo half-life, preferential stimulation of effector T-cells 
over Tregs, and reduction of IL-2-related toxic adverse effects (Table 1) [6,18,20]. 
While the process of complexing IL-2 with a specific anti-IL-2 mAb is rather simple, 
the complete dissociation of IL-2 from the mAb can be avoided by introducing a 
flexible linker between IL-2 and the mAb [21]. 
With the production of humanized or fully human anti-human IL-2 mAbs and 
the generation of single-molecule IL-2-cx, this technology might soon become 
available for testing in the clinic. 
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IL-2 muteins 
Other strategies have focused on mutated forms of IL-2 (IL-2 muteins). While some 
IL-2 muteins were designed to target dimeric IL-2Rs, hence leading to the preferential 
stimulation of memory CD8+ T-cells and NK cells, other IL-2 muteins favor cells 
expressing high levels of CD25, such as recently-activated T-cells, but also Tregs, 
the latter of which was less obvious when these molecules were engineered (Table 
1). 
 The mutein ‘IL-2 superkine’ was generated by several amino acid substitutions 
between positions 80 and 92 of IL-2 [19]. Notably, a change of leucine for valine at 
position 85 (L85V) resulted in a 5.7-fold increase of affinity for CD122, whereas a set 
of four additional mutations (L80F, R81D, I86V and I92F) led to an additional 35-fold 
increase, resulting in an overall increase of affinity for CD122 of about 200-fold over 
wild-type IL-2. IL-2 superkine was shown to bind IL-2Rs with high affinity in a CD25-
independent manner. Compared to wild-type IL-2, IL-2 superkine exerted superior 
anti-tumor properties in different murine tumor models, being comparable to CD122-
targeting IL-2-cx when using a brief treatment course of five daily injections. 
However, compared to IL-2-cx, the anti-tumor efficacy of IL-2 superkine was weaker 
and could not be significantly improved by repetitive treatment cycles or formulation 
of an IL-2 superkine-Fc construct with longer in vivo activity (unpublished data). As 
for toxic adverse effects, IL-2 superkine showed, similar to IL-2-cx, reduced IL-2-
related pulmonary edema and liver cell damage. 
 With the aim of reducing the affinity of IL-2 to CD25, another IL-2 mutein 
(termed ‘no- mutein’) was generated by introducing an alanine at positions R38, 
F42, Y45, and E62, resulting in decreased affinity for CD25 while maintaining normal 
binding with IL-2Rβγ [22]. No- mutein inhibited, in an NK-cell dependent manner, 
the metastasis of the B16 melanoma-variant MB16F0 and of 3LL-D122 Lewis lung 
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carcinoma in mice, while exerting lower toxic adverse effects compared to wild-type 
IL-2. The latter aspect was also confirmed by us using the F42A mutant of IL-2 that 
displays lower affinity to CD25, which was better tolerated in terms of pulmonary 
edema than wild-type IL-2 ([19], and unpublished data). 
 Another research group formulated various IL-2 muteins displaying higher 
affinity to CD25. In vitro, these IL-2 muteins showed superior capacity to stimulate 
CD25-expressing KIT-225 cells [23]. In vivo toxicity of these IL-2 muteins was not 
assessed, however, based on the dependency of IL-2-mediated adverse effects on 
CD25 [18], we expect to observe similar, or maybe increased, toxicity with CD25-
directed IL-2 muteins compared to IL-2. Moreover, administration of CD25-directed 
IL-2 muteins will likely result in significant expansion of Tregs, as is the case with 
other CD25-directed IL-2 formulations in mice [6,18] and with wild-type IL-2 in 
humans [24]. Notably, BAY 50-4798 is a CD25-directed human IL-2 mutein, 
containing the amino acid substitution N88R, thereby disfavoring binding to CD122 
by about 225,000-fold [25]. The rationale for generating BAY 50-4798 was to reduce 
IL-2 binding to NK cells, thereby decreasing NK-cell-derived pro-inflammatory 
cytokines contributing to VLS [26]. However, the clinical response rate following BAY 
50-4798 was low: only two out of 45 patients (4%; one renal cell carcinoma and one 
metastatic melanoma patient) receiving BAY 50-4798 experienced a partial 
response. Administration of BAY 50-4798 to patients increased counts of CD4+CD25+ 
T-cells, including Tregs, while CD8+ T-cell and NK-cell counts changed only 
minimally [27]. 
 These results show that administration of CD25-directed IL-2 formulations 
leads to preferential stimulation of CD25+ Tregs. However, CD25-directed IL-2 
formulations might be suitable when combined with antigen-specific cancer vaccines 
by boosting the expansion of recently-primed - and thus CD25+ [3,5] - tumor antigen-
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specific T-cells [15]. Yet, this approach might program T-cells to become short-lived 
effectors rather than memory cells, the latter of which receive lower intensity IL-2 
signals during their expansion phase and depend on CD122-mediated survival 
signals during memory [1]. 
 Comparing IL-2 muteins to IL-2-cx and wild-type IL-2, IL-2 muteins show 
similar pharmacokinetic properties as wild-type IL-2, such as a short in vivo half-life 
[14], and will thus require frequent administration to maintain therapeutic levels 
(Table 2). IL-2-cx do not possess this disadvantage because of their prolonged half-
life [20]. Moreover, IL-2 muteins contain a potentially immunogenic neoepitope, 
targeting of which might lead to abrogation of its biological activity. In line with this, 
27% of patients developed BAY 50-4798-specific antibodies already after one round 
of treatment [27]. Conversely, conventional IL-2-cx consist of two components able to 
fully dissociate from each other, unless they are associated by a covalent linker [21]. 
 
IL-2 fusion proteins 
Various IL-2-FPs (also termed IL-2 immunocytokines) have been generated in the 
past twenty years (reviewed in [28]). IL-2-FPs were devised to deliver the cytokine to 
the tumor microenvironment thereby increasing the local dose of IL-2 to levels 
sufficient to stimulate tumor-specific immune cells, while keeping systemic IL-2 levels 
and toxic adverse effects low. To this end, IL-2 has been fused to different antibodies 
or antibody fragments targeting tumor-associated antigens [28]. 
 Selectikine is a fully humanized IL-2-FP developed for the treatment of solid 
tumors and B-cell non-Hodgkin lymphoma [29-31]. Selectikine comprises mAb 
NHS76 recognizing single or double-stranded DNA (often released from dying tumor 
cells) and a CD25-directed IL-2 mutein with a D20T mutation aimed at disrupting a 
three-amino-acid-sequence motif in IL-2, which appears to be responsible for IL-2-
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binding to endothelial cells, thereby causing endothelial cell damage and VLS [32]. 
Compared to IL-2, Selectikine induced only mild (grade 1) hypotension and VLS 
suggesting improved tolerability [31]. Selectikine monotherapy stabilized disease for 
more than 6 weeks in 23% (9/39) and combined with low-dose cyclophosphamide in 
33% (3/9) of patients with metastatic or local advanced tumors (mostly carcinomas) 
refractory to standard treatments [30]. Despite the transient increase of total 
leukocyte, lymphocyte and monocyte counts after each infusion, treatment with 
Selectikine failed to expand tumor-specific CD8+ T-cells or promote their effector 
functions. Notably, circulating Tregs were massively expanded upon Selectikine, 
however, no correlation existed between blood Treg numbers and overall survival, 
although intratumoral Tregs were not assessed. 
 Two other IL-2-FPs (termed GA504 and GA501) consist of an IL-2 mutein with 
abolished binding to CD25 fused to humanized mAbs targeting carcinoembryonic 
antigen (CEA). GAS504, given three times weekly, has been reported to strongly 
expand and activate NK cells, CD8+ T-cells and γδ T-cells and lead to favorable ratios 
of CD8+ to CD4+ T-cells in blood, lymphoid organs and the tumor site. GA504 and 
GA501 were more efficient in controlling tumor growth of the syngeneic MC38-CEA 
and PancO2-CEA murine tumors compared to non-targeted IL-2-FP or wild-type IL-2 
[33,34].  
Another IL-2-FP undergoing clinical testing is hu14.18–IL-2. This 
immunocytokine is made of wild-type human IL-2 linked to each IgG heavy chain of 
the hu14.18 mAb, which recognizes disialoganglioside on tumors of neuroectodermal 
origin, such as neuroblastoma and melanoma [35]. In a phase II clinical trial, fourteen 
patients received at least two treatment cycles of hu14.18–IL-2, resulting in one 
partial response (7.1%) [36]. Subsequently, intratumoral administration of hu14.18–
IL-2, instead of iv, was tested in the murine NXS2 neuroblastoma model, leading to 
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increased intratumoral infiltration of NK cells and CD8+ T-cells and improved anti-
tumor effects [37]. However, intratumoral administration might limit the application of 
hu14.18–IL-2 to patients with solid tumors accessible for injection. 
Interestingly, intratumoral administration was shown to induce also systemic 
immune responses as demonstrated recently using L19–IL2, an IL-2-FP binding the 
alternatively spliced extra-domain B of fibronectin [38]. Twenty-five patients received 
once weekly ten million IL-2 international-unit equivalents of L19–IL2 with all lesions 
visible at screening being injected. Treatment resulted in an objective responses rate 
of 53.9% with 6 patients (25%) experiencing a complete disappearance of all treated 
lesions. Administration of L19–IL2 led to a transient increase of peripheral Tregs and 
NK cells, while lowering the numbers of myeloid-derived suppressor cells in blood. 
Toxic adverse effects were comparable to wild-type IL-2. 
Another example of the potent therapeutic effects induced by targeting IL-2 to 
blood vessels was shown by administration of F16-IL2 and cytarabine to a patient 
with disseminated extramedullary acute myeloid leukemia [39]. 
 
IL-15-based immunotherapeutics 
IL-15 shares many similarities to IL-2 as it also binds to CD122 and c. However, 
instead of CD25, IL-15 interacts with high affinity (Kd≈10-11 M) with its private -
chain, termed IL-15R or CD215. IL-15 signaling is facilitated via cis or trans-
presentation of IL-15 by IL-15R [40]. Unlike IL-2, IL-15 minimally stimulates CD25+ 
Tregs and causes less CD25-mediated toxicity, while efficiently activating CD8+ T-
cells and NK cells [7]. We assessed IL-15 and several IL-15-based formulations with 
extended in vivo half-lives in comparison to IL-2 and IL-2-cx. IL-15-based 
formulations included complexes of IL-15 with recombinant IL-15R linked to Fc (IL-
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15/IL-15R-Fc), IL-15/anti-IL-15 mAb complexes, and IL-15 coupled covalently via a 
linker to IL-15R (termed RLI, [41]). IL-2-cx conferred slightly better tumor control 
against subcutaneous B16F10 melanoma than the IL-15-based formulations, and 
both groups of formulations largely surpassed IL-2 and IL-15 for anti-tumor efficacy. 
This effect was paralleled by CD8+ T-cell expansion. Interestingly, modest Treg 
expansion occurred following IL-2-cx but also IL-15 formulations, with the latter also 
appearing to affect myeloid-derived cell subsets (unpublished data). In line with our 
observations, the potential for clinical application of IL-15 formulations for cancer 
immunotherapy has been shown in B16F10 melanoma and pancreatic cancer in 
RIP1-Tag2 mice [42,43]. Significant reduction in tumor burden and increased survival 
of mice treated with IL-15IL-15Rα-FP was observed, while treatment with IL-15 
showed a negligible effect in these settings. 
 
Final comments and conclusions 
IL-2 cancer immunotherapy is experiencing a revival thanks to the advent of several 
IL-2 formulations, especially CD122-directed and tumor-targeting compounds, with 
superior immune stimulatory properties and robust anti-tumor efficacy in pre-clinical 
and early clinical situations compared to wild-type IL-2. The majority of these novel 
IL-2 formulations display significantly reduced toxic adverse effects in comparison to 
IL-2. While improved IL-2 formulations might be useful as monotherapies, their 
combination with other anti-cancer immunotherapies, such as adoptive T-cell transfer 
regimens, antigen-specific vaccination, and blockade of inhibitory molecules, e.g. 
cytotoxic T-lymphocyte antigen-4 and programmed cell death-1, to expand and 
maintain efficacious tumor-specific T-cell responses, might hold the promise of 
controlling metastatic cancer. 
 12 
 
Acknowledgements 
We thank the members of the Boyman laboratory for critical reading of the manuscript. This 
work was funded by Swiss Cancer League grants KFS-02672-08-2010, SNF grants PP00P3-
128421 and CRSII3-136203 (all to O.B.). 
Conflict-of-interest disclosure: The authors declare no competing financial interests. 
 
  
 13 
 
  
 
Figure 1. Properties of different IL-2 receptors and CD122-directed IL-2-cx. (A) 
IL-2 can be bound by CD25 (also known as IL-2 receptor , IL-2R) alone, a 
heterodimer of CD122 (IL-2R) and c (common -chain receptor or alternatively 
known as IL-2R), or a heterotrimer of CD25, CD122 and c. CD122 and c are able 
to signal, whereas CD25 increases IL-2R affinity [1,2,4,8]. (B) Preferential stimulation 
of cells expressing high levels of CD122 is achieved by complexing IL-2 with a 
particular anti-IL-2 mAb (such as clone S4B6 for murine IL-2), which binds IL-2 at a 
site within or neighboring the CD25-binding site thus impairing binding to CD25 and 
trimeric IL-2Rs [1,6,20]. 
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Figure 2. Overall survival of stage IV melanoma patients with or without high-dose IL-
2 treatment. Shown are survival data of untreated patients with stage IV melanoma 
and of stage IV melanoma patients following high-dose (HD) IL-2 immunotherapy, 
adapted from [44] and [10], respectively. 
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Table 1. Biochemical, pharmacological and immunological properties of IL-2 
formulations compared to IL-15 compounds. 
Compound 
Binding to 
CD25 
Binding to 
CD122 
Stimulation of 
CD4
+
CD25
+
 
Tregs 
Stimulation 
of CD8
+
 T-
cells 
Stimulation 
of NK cells 
Half-life in 
blood (hours) 
Ref. 
Wild-type IL-2        
HD IL-2 ++ + +++ ++ ++ + (0.5-1 h) [9,45] 
LD IL-2 ++ + ++ + + + (0.5-1 h) [45] 
IL-2-cx  + ++ ++++ +++ +++ (>24 h) [15,18] 
IL-2 muteins        
CD25-directed 
IL-2 muteins 
+++ + +++ (in vitro) 
○
 ND ND + [23] 
BAY 50-4798 ++  +++ + + + [25,27] 
IL-2-superkine ++ +++ ++ +++ +++ + [19] 
No- mutein + + + + + + [22] 
IL-2-FPs        
hu14.18–IL-2  ++ + ND ND ND ++ (2-4 h) [46] 
F8-IL2 / F16-IL2 ++ + ND ND ND +++ 
#
 [39] 
L19-IL2 ++ + ++ ++ ++ +++ [47,48] 
IL-2-mutein-FPs        
Selectikine ++ + +++ ND + ++ (5 h) [30,31] 
CEA-IL2v 
(GA504 & GA501) 
 + +/++ +++ +++ +++ 
#
 [33,34] 
IL-15 formulations        
IL-15/mAb-cx  + +/++ +++ +++ +++ 
#
 UP 
IL-15/IL-15R-cx  +++ +/++ +++ +++ +++ 
#
 [42] 
RLI  +++ +/++ +++ +++ ++ (3 h) [41] 
 
ND = not determined, UP = unpublished data.
 
– no effect, + weak,
 
++ mild, +++ strong, ++++ very strong, compared to control. 
○ 
The human CD25
+
 KIT-225 T-cell line was used to assess potency of IL-2Rα-targeting muteins [23]. 
#
 Estimated. 
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Table 2. Therapeutic anti-tumor properties of IL-2 formulations compared to IL-15 
compounds. 
Compound 
Anti-tumor efficacy Adverse effects 
Ref. 
Pre-
clinical 
a 
Clinical objective response (%)
 
Pre-clinical 
a Clinical 
(grade 3 and 4) 
b 
0 – 0.5 years 0.5 – 5 years > 5 years 
Wild-type IL-2        
HD IL-2 ++
[18]
 40-48% 10-36% 8-9.3% +++ 36 - 45% ˟ [9,45] 
LD IL-2 + ND ND ND + 2.9% ˟ [45] 
IL-2-cx  +++ ND ND ND + ND [15,18] 
IL-2 muteins        
CD25-directed 
IL-2 muteins 
ND ND ND ND ND ND [23] 
BAY 50-4798 +++ 0% (0/48) ND ND + 70-80%  [25,27] 
IL-2-superkine ++/+++ ND ND ND + ND [19] 
No- mutein +++ ND ND ND + ND [22] 
IL-2-FPs        
hu14.18–IL-2 ++/+++ 0% (0/9)  
□
 ND ND + 41%  [46] 
F8-IL2 / F16-IL2 +++ 
1/1 (case 
study)  
ND ND + ND [39] 
L19-IL2 +++ 53.9% ND ND ND 10-20% [47,48] 
IL-2-mutein-FPs        
Selectikine ++ 7-14%  ND ND + 10% [30,31] 
CEA-IL2v 
(GA504 & GA501) 
+++ ND ND ND ND ND [33,34] 
IL-15 formulations        
IL-15/mAb-cx ++ ND ND ND + ND UP 
IL-15/IL-15R-cx ++/+++ ND ND ND + ND [42] 
RLI ++/+++ ND ND ND + ND [41] 
ND = not determined, UP = unpublished data; objective responses = % of complete plus partial 
response of treated patients, excluding stable disease. 
 
Clinical adverse effects of IL-2 are shown only for grade 3 and 4 reactions, whereby (˟) indicates 
hypotension. 
 
□ 
A 98% humanized version of the hu14.18-IL-2 containing a single point mutation (K322A), termed 
hu14.18K322A showed better objective responses (6/31, 20%) in patients with recurrent 
neuroblastoma [49]. 
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Highlights 
• IL-2 immunotherapy can induce durable tumor regression of metastatic cancer. 
• IL-2 can lead to toxic adverse effects and stimulate regulatory CD4
+
 T cells. 
• Compared to IL-2, CD122-directed IL-2 formulations show a better therapeutic profile. 
• CD122-directed formulations include IL-2/anti-IL-2 mAb complexes and IL-2 muteins. 
 
 
